Recent Press Releases

NIH Funds Influenza Research and Surveillance Network

NIH Funds Influenza Research and Surveillance Network NIAID-Supported Centers Integrate Research to Improve Pandemic Preparedness Influenza scientists at five sites in the United States are to...

Gardasil® approved in the European Union for a 2-dose schedule in children aged from 9 to 13 years

A new 2-dose regimen for Gardasil®, quadrivalent HPV vaccine, now available for adolescents Lyon, France – April 7th 2014 – Sanofi Pasteur MSD announced today that the European...

Pitt CVR and Sanofi Pasteur Collaborate to Assess the Effectiveness of a Dengue Vaccine

Pitt CVR and Sanofi Pasteur Collaborate to Assess the Effectiveness of a Dengue Vaccine PITTSBURGH, April 15, 2014 – The University of Pittsburgh Center for Vaccine Research (CVR) and Sanofi...

NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION

NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION Funding Will Accelerate Expansion of European Manufacturing BETHESDA, Md., April 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: ...

Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThrax

Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThrax ROCKVILLE, Md.--(BUSINESS WIRE)--April 16, 2014-- Emergent BioSolutions Inc....

NIH Funds Influenza Research and Surveillance Network

NIH Funds Influenza Research and Surveillance Network NIAID-Supported Centers Integrate Research to Improve Pandemic Preparedness Wednesday, April 9, 2014 ​Influenza scientists at five sites...

Mucosis Announces a Strategic Partnership with Changchun Bcht Biotechnology of China and Raises Additional Capital

Mucosis Announces a Strategic Partnership with Changchun Bcht Biotechnology of China and Raises Additional Capital Groningen, the Netherlands, April 15, 2014 / B3C newswire / - Biotechnology company...

Mucosis Announces a Strategic Partnership with Changchun Bcht Biotechnology of China and Raises Additional Capital

Mucosis Announces a Strategic Partnership with Changchun Bcht Biotechnology of China and Raises Additional Capital Groningen, the Netherlands, April 15, 2014 / B3C newswire / - Biotechnology company...

Anuradha Gupta appointed Deputy CEO of the GAVI Alliance

Anuradha Gupta appointed Deputy CEO of the GAVI Alliance Geneva, 10 April 2014 - The GAVI Alliance is delighted to announce the appointment of Anuradha Gupta as its new Deputy CEO. With more...

Evolution of whooping cough bacterium could reduce vaccine effectiveness

The bacterium that causes whooping cough, Bordetella pertussis, has changed – most likely in response to the vaccine used to prevent the disease – with a possible reduced effectiveness of...

Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)

Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM) BERKELEY, CA--(Marketwired - Apr 15, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical...

Novartis Vaccines appoints new Medical Affairs Director for North Europe

Novartis Vaccines appoints new Medical Affairs Director for North Europe 14 April 2014 – Novartis Vaccines is pleased to announce the appointment of Dr John Porter to the position of Medical...

Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting

Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting Study findings show enhanced therapeutic potential for...

Stemline Therapeutics Announces FDA Acceptance of IND for SL-701, a Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors

Stemline Therapeutics Announces FDA Acceptance of IND for SL-701, a Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors NEW YORK, Apr 08, 2014 (GLOBE NEWSWIRE via COMTEX) -- Stemline...

Novavax Appoints Dr. Cindy Oliver as Senior Vice President, Process Development Operations

Novavax Appoints Dr. Cindy Oliver as Senior Vice President, Process Development Operations GAITHERSBURG, Md., April 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage...

Public health: Joint purchasing of vaccines and medicines becomes a reality in the EU

Public health: Joint purchasing of vaccines and medicines becomes a reality in the EU Brussels, 10 April 2014 Today, the Commission approved a Joint Procurement Agreement, which will enable all EU...

Merck Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

Merck Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer First patient dosed in tecemotide Phase III trial; study recruiting across 250...

Novartis meningitis B vaccine Bexsero(R) receives FDA Breakthrough Therapy designation in the US

Novartis meningitis B vaccine Bexsero(R) receives FDA Breakthrough Therapy designation in the US (Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis meningitis B vaccine...

THOMAS MONATH AND RUSSELL MIDDAUGH JOIN SCIENTIFIC ADVISORY BOARD OF VAXESS TECHNOLOGIES

Innovative vaccine stabilization company adds experts with extensive experience in vaccine development and formulation CAMBRIDGE, Massachusetts—April 4, 2014—Vaxess Technologies, Inc.,...

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced...